Tests a connected scale to monitor lymphoma or myeloma patients
Tests remote weight tracking in adults with lymphoma or myeloma on chemotherapy.
Plain-language title generated from the registry record
Registry title: Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
Key facts
- Where
- Paris, FranceSee the site
Where in France
- Cochin HospitalParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT06133426
- Record updated
- 15 September 2025
- Original description
In this research, we will evaluate the feasibility of following by remote monitoring, using a connected scale, in hematology patients suffering from myeloma or lymphoma and requiring treatment with chemotherapy. 30 patients will be included in the research and will all use a connected scale for the duration of their participation (7 weeks +/- 1 week). During their participation, patients will be asked to weigh themselves once a day, ideally at a set time. Patient data will be accessible by the medical team via a remote monitoring platform.Read full original descriptionShow less
Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
In this research, we will evaluate the feasibility of following by remote monitoring, using a connected scale, in hematology patients suffering from myeloma or lymphoma and requiring treatment with chemotherapy. 30 patients will be included in the research and will all use a connected scale for the duration of their participation (7 weeks +/- 1 week). During their participation, patients will be asked to weigh themselves once a day, ideally at a set time. Patient data will be accessible by the medical team via a remote monitoring platform.
Alerts will be generated in the event of abnormal development of certain clinical parameters (weight, heart rate, etc.) allowing early treatment to be implemented by the medical team.
At the end of their participation, we will evaluate patients' support and perception of this tool, as well as the healthcare consequences of the alerts generated by the remote monitoring platform.
Inclusion: Patient aged 18 and over (male or female); Patient suffering from aggressive non-Hodgkin's lymphoma or multiple myeloma with a plan for systemic chemotherapy or having started two cycles or less or patient with the need for therapeutic intensification under the cover of autograft in the context of myeloma or lymphoma; Patient who can be contacted by telephone during their participation in the research; Patient able to return home at the end of their initial hospitalization; Patient affiliated to social security; Patient able to read and speak French; Patient having signed free, informed and written consent.
Exclusion: Patient with moderate to severe cognitive impairment (assessed by MMSE < 20); Patient with a psychiatric or physical disability that does not allow the use of the device; Patient with an estimated life expectancy < 3 months; Patient with a pacemaker; Patient participating in another intervention research project; Pregnant patient; Patient deprived of liberty; Patient under legal protection (guardianship or curatorship).